Zobrazeno 1 - 10
of 2 079
pro vyhledávání: '"Metastatic Urothelial Carcinoma"'
Autor:
Shintaro Mori, Tomohiro Matsuo, Hiroyuki Honda, Kyohei Araki, Kensuke Mitsunari, Kojiro Ohba, Yasushi Mochizuki, Ryoichi Imamura
Publikováno v:
IJU Case Reports, Vol 7, Iss 4, Pp 324-328 (2024)
Introduction Few studies have reported on administering enfortumab vedotin to patients with metastatic urothelial carcinoma and end‐stage renal disease requiring hemodialysis. Case presentation Case 1: An 85‐year‐old man underwent hemodialysis
Externí odkaz:
https://doaj.org/article/d59e284047034cfba021b9c6b95466f2
Autor:
Akinori Minato, Nobuki Furubayashi, Yujiro Nagata, Toshihisa Tomoda, Hiroyuki Masaoka, Yoohyun Song, Yoshifumi Hori, Keijiro Kiyoshima, Takahito Negishi, Kentaro Kuroiwa, Narihito Seki, Ikko Tomisaki, Kenichi Harada, Motonobu Nakamura, Naohiro Fujimoto
Publikováno v:
Current Oncology, Vol 31, Iss 2, Pp 862-871 (2024)
Subtype of urothelial carcinoma (SUC), defined here as urothelial carcinoma with any histologic subtype or divergent differentiation, is a clinically aggressive disease. However, the efficacy of enfortumab vedotin (EV) against SUC remains unclear. He
Externí odkaz:
https://doaj.org/article/090e7c2b79cf474b85e1f11873b1d392
Autor:
Yuki Endo, Jun Akatsuka, Hayato Takeda, Hiroya Hasegawa, Masato Yanagi, Yuka Toyama, Hikaru Mikami, Mikio Shibasaki, Go Kimura, Yukihiro Kondo
Publikováno v:
Current Oncology, Vol 31, Iss 2, Pp 759-768 (2024)
This study presents the enfortumab vedotin (EV) treatment analysis at our institution. We retrospectively analyzed patients with metastatic urothelial cancer (mUC) treated with EV between January 2021 and October 2023. EV was administered at 1.25 mg/
Externí odkaz:
https://doaj.org/article/5caa66cc1ed94b8f9699de01dd1e1ce1
Autor:
Jingwei Xu, Hongqiao Zhang, Li Zhang, Xiufeng Chu, Yu Li, Guangyuan Li, Caiyun Nie, Meng Wang, Yanwei Guo
Publikováno v:
Cancer Medicine, Vol 12, Iss 23, Pp 21159-21171 (2023)
Abstract Introduction Previous RC48 (Disitamab Vedotin) studies established that the safety and efficacy of RC48‐antibody–drug conjugate (ADC), either alone or combined with toripalimab, for metastatic urothelial carcinoma (mUC) patients exhibiti
Externí odkaz:
https://doaj.org/article/29bda2583f114e028fc4b347180d8a2a
Publikováno v:
Xin yixue, Vol 54, Iss 9, Pp 611-617 (2023)
Metastatic urothelial carcinoma (mUC) yields poor prognosis and is difficult to treat. Immunotherapy strategies have developed rapidly in recent years, and clinical prognosis of mUC patients has been significantly improved. However, immune ch
Externí odkaz:
https://doaj.org/article/582b3a2345474052953e896234600c2a
Autor:
Tsung-Han Tsai, Po-Jung Su, Shih-Yu Huang, Ming-Chun Kuo, Chang-Ting Lin, Chia-Che Wu, Hao-Lun Luo, Chien-Hsu Chen, Chih-Chi Chou, Ting-Ting Liu, Chun-Chieh Huang, Kai-Lung Tsai, Yu-Li Su
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background While the treatment guidelines have been established for pure urothelial carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face limited effective treatment options. The effectiveness of immune checkpoint inhib
Externí odkaz:
https://doaj.org/article/10619625828044718e74366ce2c048cc
Autor:
Andrea Katharina Lindner, Felizian Lackner, Piotr Tymoszuk, Dominik Andreas Barth, Andreas Seeber, Florian Kocher, Bettina Toth, Margarethe Hochleitner, Martin Pichler, Renate Pichler
Publikováno v:
Biology of Sex Differences, Vol 14, Iss 1, Pp 1-17 (2023)
Abstract Introduction Clinical trials investigating efficacy of immune checkpoint inhibitors (ICI) revealed sex-specific divergent outcomes in urothelial cancer (UC), suggesting that sex hormones might play an important role in gender-specific dimorp
Externí odkaz:
https://doaj.org/article/f586a4446c9c46e996ae7923030ddea9
Autor:
Bunpei Isoda, Masanobu Shiga, Shuya Kandori, Yoshiyuki Nagumo, Takayuki Yoshino, Atsushi Ikeda, Takashi Kawahara, Tomokazu Kimura, Hiromitsu Negoro, Akio Hoshi, Bryan J Mathis, Hiroyuki Nishiyama
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 414-418 (2023)
Enfortumab vedotin (EV) is an antibody-drug conjugate and a promising agent for metastatic urothelial carcinoma (mUC). However, evaluations in end-stage renal disease patients undergoing hemodialysis are unreported. Here, we report such a case. A 74-
Externí odkaz:
https://doaj.org/article/cb161f89c008410ba2347449bc2267e9
Autor:
Yousuke Fukiishi, Hideo Fukuhara, Yoshitaka Kurano, Hiroki Shugimoto, Erika Yamashita, Takashi Karasima, Keiji Inoue
Publikováno v:
IJU Case Reports, Vol 6, Iss 2, Pp 128-132 (2023)
Introduction Immune checkpoint inhibitors such as programmed cell death/−ligand 1 inhibitor and cytotoxic T‐lymphocyte‐associated antigen‐4 inhibitors have been widely used for various advanced malignancies. The mechanism of action for these
Externí odkaz:
https://doaj.org/article/7bb9ad9292c84bc0815f4998950ed395
Autor:
Keren Rouvinov, Eran Levanon, Avivit Peer, Michal Sarfaty, David Sarid, Victoria Neiman, Eduard Grikshtas, Eli Rosenbaum, Igal Kushnir, Barak Talmor, Michael Friger, Yonaton Zarbiv, Eli Gez, Hadas Dresler, Walid Shalata, Amichay Meirovitz, Noa Shani Shrem, Alexander Yakobson, Wilmosh Mermershtain, Daniel Keizman
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundErdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor is a standard post chemotherapy advanced treatment line for metastatic urothelial carcinoma harboring FGFR2/3 genomic alterations. It was approved based on a phase 2 clinical
Externí odkaz:
https://doaj.org/article/5d97724776e04b738ec6fc3ae439db56